What does this company do and how does it make money?

DexCom sells disposable glucose sensors that diabetics replace every 10-14 days, creating recurring revenue streams. The company is transitioning from rapid growth in its core type 1 diabetes market to broader adoption in the much larger type 2 diabetes and consumer wellness markets, explaining both the growth deceleration and margin expansion as the business matures.

Five legendary investment frameworks analyzed this company.

Lynch sees DexCom's 24x earnings as unjustifiable for 4.2% growth, while Graham finds 92% upside despite the company's 1.04% earnings yield trailing treasuries by 332%. Tap any framework below to explore their complete analysis and discover where the legends agree — and where they diverge.

How much cash does it generate and where does it go?

DexCom generates substantial cash and splits it between heavy R&D investment to maintain its technology edge and recent aggressive share repurchases. The shift to buybacks marks a new capital allocation strategy, though at an average price of $128.02 versus the current $62.22, these repurchases are underwater by 51.4%.

Is the business getting stronger or weaker?

DexCom is trading growth for profitability in a textbook transition from hypergrowth to mature operations. The 7.99x operating leverage means small revenue gains translate to massive profit improvements, but this sword cuts both ways — any revenue weakness will disproportionately impact earnings.

What could go wrong and has it survived trouble before?

DexCom has proven resilient through multiple crises, recovering within one quarter from each shock. The main risk is the high operating leverage that magnifies revenue volatility, though the fortress balance sheet and management's insider buying suggest they see the current 66% drawdown as opportunity rather than justified concern.

ROIC hit a record 6.01% in the same quarter revenue growth slowed to 4.2% — excellence in execution as expansion ends.

Is the stock priced for perfection, fair value, or pessimism?

Despite trading near 52-week lows, DexCom remains expensive on traditional metrics with its earnings yield far below risk-free rates. The market demands perfection — even genuine earnings beats barely move the stock while any disappointment triggers severe punishment, suggesting investors should wait for better entry points.